<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928964</url>
  </required_header>
  <id_info>
    <org_study_id>P/2017/342</org_study_id>
    <nct_id>NCT03928964</nct_id>
  </id_info>
  <brief_title>MEtatastic Renal Carcinoma LINes</brief_title>
  <acronym>MERLIN</acronym>
  <official_title>Pronostic Assessment of Mortality Among Locally Advanced or Metastatic Renal Cell Carcinoma Patients After First Line Treatment : Multicenter Prospective Cohort Study With Historic Medical Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study are as follows:

        -  Prognostic evaluation of patients based on an integrative model provides better
           assessment of overall survival, and thus improves setting of care goals.

        -  In a routine care population, antitumour drugs may have a significant impact on overall
           survival through their targeted antitumor effect, but also through their toxicity
           profile and their impact on comorbidities.

        -  The optimization of patient support (supportive care, drug tolerance monitoring) can
           have an impact on the prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Actual">October 3, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival after the first line of treatment</measure>
    <time_frame>year 11</time_frame>
    <description>Time elapsed between initiation date for 2nd line treatment et the date of death, whatever the cause.</description>
  </primary_outcome>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced or metastatic renal cell carcinoma, whose first-line
        treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or
        monoclonal antibodies) and / or an mTOR inhibitor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with locally advanced or metastatic renal cell carcinoma

          2. Whose first-line treatment included at least one anti-angiogenic agent (tyrosine
             kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor;

          3. Whatever was the overall ECOG-PS score (Eastern Cooperative Oncology Group Performance
             Status) at treatment initiation time

          4. With first-line treatment carried out between 2007 and June 2016.

        Exclusion criteria:

          1. Patient previously treated with only one cytokine (Interferon α2a, high-dose
             interleukin-2)

          2. Refusal of processing of personal data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Rousseau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Henri Mondor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté Montbéliard</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées de Bégin</name>
      <address>
        <city>Saint-Mandé</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

